Biocept, Inc. (BIOC) Analysts See $-0.19 EPS

March 18, 2018 - By Darrin Black

 Biocept, Inc. (BIOC) Analysts See $ 0.19 EPS

Analysts expect Biocept, Inc. (NASDAQ:BIOC) to report $-0.19 EPS on March, 28 after the close.They anticipate $0.08 EPS change or 29.63 % from last quarter’s $-0.27 EPS. After having $-0.20 EPS previously, Biocept, Inc.’s analysts see -5.00 % EPS growth. The stock decreased 3.25% or $0.0112 during the last trading session, reaching $0.3338. About 3.76M shares traded or 61.03% up from the average. Biocept, Inc. (NASDAQ:BIOC) has declined 31.06% since March 18, 2017 and is downtrending. It has underperformed by 47.76% the S&P500.

Biocept, Inc. (NASDAQ:BIOC) Ratings Coverage

Among 3 analysts covering Biocept Inc (NASDAQ:BIOC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biocept Inc had 4 analyst reports since August 19, 2015 according to SRatingsIntel. Roth Capital initiated the shares of BIOC in report on Monday, June 6 with “Buy” rating. H.C. Wainwright initiated the shares of BIOC in report on Wednesday, August 19 with “Buy” rating.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $21.23 million. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.